On being appointed the Daniel P.S. Paul Professor of Constitutional Law, Tomiko Brown-Nagin delivered a lecture titled, “On Being First: Judge Constance Baker Motley and Social Activism in the American Century,” which focused on 20th century social reform through the life of the Motley, a civil rights advocate who became the first female African American federal judge in 1966.
Harvard Law School Professor I. Glenn Cohen, faculty director of the School’s Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics spoke with the Harvard Gazette about Monday’s ruling by the Supreme Court that overturned a Texas law requiring that abortion clinics maintain hospital-like standards at their facilities as well as admitting privileges at local hospitals.
Deborah Anker and Phil Torrey weigh in on the 4-4 Supreme Court tie that dealt a major blow to President Obama’s executive actions to grant relief from deportation to undocumented immigrants living in the U.S.–putting, according to Anker, ‘hundreds of thousands of people at risk of deportation, including parents of U.S. citizens or legal residents.’
With the passing of Justice Antonin Scalia ’60 of the U.S. Supreme Court on February 13 has come an outpouring of remembrances and testaments to his transformative presence during his 30 years on the Court. On February 24, Dean Martha Minow and a panel of seven Harvard Law School professors, each of whom had a personal or professional connection to the justice, gathered to remember his life and work.
It is the rare law review article that directly leads the Supreme Court to change how it does business. But that’s exactly what happened after the Harvard Law Review published an article in 2014 by Richard Lazarus, revealing how Supreme Court opinions get changed after issuance, with little public notice.
“FDA in the 21st Century: The Challenges of Regulating Drugs and New Technologies,” edited by Holly Fernandez Lynch and I. Glenn Cohen ’03 (Columbia). Stemming from a 2013 conference at HLS, the book features essays covering major developments that have changed how the FDA regulates; how the agency encourages transparency; First Amendment issues; access to drugs; and evolving issues in drug-safety communication. These issues, the editors write, lie “at the heart of our health and health care.”